EXALEAD – Trademark Portfolio
Entity Type: 99
EXALEAD holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 7 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EXALEAD and CLOUDVIEW. The owner is based in 75008 PARIS.
10 PLACE DE LA MADELEINE
75008 PARIS , FR
Showing of trademarks Trademarks
Trademark Classifications
EXALEAD's trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does EXALEAD have?
EXALEAD has 10 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 4 cancelled.
What trademark classes does EXALEAD file in?
EXALEAD files trademarks across 7 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 38 (Telecommunications), Class 35 (Advertising & Business), Class 41 (Education & Entertainment). Class 42 covers scientific and technological services; industrial analysis and research services.
What are EXALEAD's most well-known trademarks?
EXALEAD's registered trademark portfolio includes well-known marks such as EXALEAD and CLOUDVIEW. These are among 2 currently registered trademarks in the portfolio.
What is EXALEAD's trademark registration success rate?
EXALEAD has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.